Inhibikase Therapeutics Stock Today
| IKT Stock | USD 2.37 0.05 2.07% |
PerformanceVery Weak
| Odds Of DistressAverage
|
Inhibikase Therapeutics is selling for under 2.37 as of the 22nd of March 2025; that is 2.07 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 2.36. Inhibikase Therapeutics has 54 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 23rd of December 2020 | Category Healthcare | Classification Health Care |
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinsons Disease and related disorders that arise inside and outside of the brain. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia. The company has 72.68 M outstanding shares of which 1.26 M shares are currently shorted by investors with about 5.58 days to cover. More on Inhibikase Therapeutics
Moving together with Inhibikase Stock
Moving against Inhibikase Stock
Inhibikase Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President Development | FACC MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsInhibikase Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Inhibikase Therapeutics' financial leverage. It provides some insight into what part of Inhibikase Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inhibikase Therapeutics (IKT) is traded on NASDAQ Exchange in USA. It is located in 3350 Riverwood Parkway SE, Atlanta, GA, United States, 30339 and employs 8 people. Inhibikase Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 175.89 M. Inhibikase Therapeutics runs under Biotechnology sector within Health Care industry. The entity has 72.68 M outstanding shares of which 1.26 M shares are currently shorted by investors with about 5.58 days to cover.
Inhibikase Therapeutics has about 32.21 M in cash with (18.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.28.
Check Inhibikase Therapeutics Probability Of Bankruptcy
Ownership AllocationInhibikase Therapeutics has a total of 72.68 Million outstanding shares. The majority of Inhibikase Therapeutics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Inhibikase Therapeutics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Inhibikase Therapeutics. Please pay attention to any change in the institutional holdings of Inhibikase Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Inhibikase Ownership Details
Inhibikase Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2024-12-31 | 322.9 K | |
| Millennium Management Llc | 2024-12-31 | 142.2 K | |
| Blair William & Co | 2024-12-31 | 135 K | |
| Barclays Plc | 2024-12-31 | 84 K | |
| Citigroup Inc | 2024-12-31 | 77.1 K | |
| Northern Trust Corp | 2024-12-31 | 64 K | |
| Omers Administration Corp | 2024-12-31 | 54.6 K | |
| Hrt Financial Llc | 2024-12-31 | 46.4 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 44 K | |
| Sands Capital Ventures, Llc | 2024-12-31 | 10.9 M | |
| Soleus Capital Management, L.p. | 2024-12-31 | 6.3 M |
Inhibikase Therapeutics Historical Income Statement
Inhibikase Stock Against Markets
Inhibikase Therapeutics Corporate Management
| Roger Rush | Head Research | Profile | |
| John Adams | Chief Officer | Profile | |
| Mark Iwicki | Chief Officer | Profile | |
| BSc FRCPC | Interim Advisor | Profile | |
| Garth LeesRolfe | Chief Officer | Profile |
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.